JAGSNPHARMBSEJagsonpal Pharmaceuticals Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 29 Jun, 2026 · 16:30 IST

Jagsonpal to acquire 85% stake in Aequitas Healthcare for Rs 20.8 Cr

Listed Co AcquisitionStrategic Transactions View source PDFExplain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.3%Reaction day
₹230.11
prior close
₹243.69
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+3.2% vs market
Pharmaceuticals peers, median of 165sector+0.8%+3.5% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.6
10m
+6.0
15m
+6.7
30m
+6.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.3+1.0+3.2+0.8+3.5
Next day
+3.2+1.2+2.0+0.3+2.9
2d
+2.1+2.1+0.0+0.8+1.2
3d
+3.3+1.7+1.6+1.2+2.2
4d
+3.4+1.9+1.4+0.6+2.8
5d
+3.9+1.2+2.6+0.1+3.7
1w
+0.7+1.1-0.4+0.6+0.1
15d
-3.5+1.6-5.2+1.8-5.4
1m
+1.0+0.1+1.0-0.5+1.6
2m
+4.9+6.6-1.8+2.7+2.2
3m
+3.1+5.5-2.3+3.3-0.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals will acquire 85% stake in Aequitas Healthcare for Rs 20.8 crore in cash, funded from internal accruals. Aequitas is a Mumbai-based pharma firm focused on hospital sales, with FY26 revenue of Rs 53.31 crore. The deal gives Jagsonpal entry into the hospital channel and institutional doctor network. Not a related party transaction. Expected to close by July 15, 2026.

Likely market impact

Strategic entry into hospital channel. Rs 20.8 Cr cash deal funded internally, no debt impact. Aequitas adds about Rs 53 Cr annual revenue.